<DOC>
	<DOCNO>NCT01644786</DOCNO>
	<brief_summary>The purpose biobank enable future genomic base research Head Neck Cancer patient population . The investigator try identify tumor factor predict cancer-related outcome order improve outcome prediction treatment patient-individualized manner .</brief_summary>
	<brief_title>The Head Neck Tumor Biobank</brief_title>
	<detailed_description>This prospective , non-interventional longitudinal study patient HNSCC . Patients normal routine workup include standard panendoscopy , usually multiple biopsy diagnostic histo-pathology obtain . Part one biopsy store HN Tumor Biobank . There change subsequent propose treatment , may consist primary surgery ( without postoperative ( chemo- ) radiation ) definitive ( chemo- ) radiation . The primary general objective project develop , validate , improve predictive model different endpoint relevant patient curatively intend treatment HNSCC . These endpoint include loco-regional tumour control overall survival . Primary Objective : To build biobank tumor tissue HNSCC patient future genomic analysis . Secondary Objective : To improve outcome prediction , base clinical factor tumour gene expression profile . Hypothesis : Our general hypothesis accurate estimation locoregional control overall survival achieve prognostic factor take account different currently use 'classical ' prognostic factor , TNM-stage . The investigator hypothesize final outcome project allow u improve performance predictive model HNSCC . The performance prediction model quantify AUC binary outcome measure c-statistic survival analysis . The ultimate objective achieve AUC least 0.90 . Such performance allow u build Decision Support System base predictive model provide information physician regard probability loco-regional failure overall survival individual patient . Study parameters/endpoints : Because specific gene-signature yet define applicable large population HNSCC patient , specific endpoint name . However , main study endpoint accuracy certain gene-signature may contribute rather improve outcome prediction patient . Outcome define locoregional control and/or survival . The outcome patient currently record electronic medical chart azM Maastro Clinic time analysis , clinical outcome data couple blind data generate tumor-biopsy analysis The goal achieve AUC least 0.90 . Such performance allow u build Decision Support System .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Patient ( suspect ) mucosal HNSCC Tumor site : oropharynx , hypopharynx , larynx , nasopharynx , oral cavity Scheduled panendoscopy general anesthesia Tumor size permit harvest multiple biopsy , without risk functional damage No previous treatment , except previous biopsy Age &gt; = 18 year Small primary tumor , e.g . vocal cord tumor , small obtain multiple biopsy associate risk functionale damage Patients undergoing panendoscopy routine clinical workup , e.g . examination general anaesthesia already perform elsewhere , referral azM .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>head neck</keyword>
	<keyword>HNSCC</keyword>
	<keyword>orophaynx</keyword>
	<keyword>hypopharynx</keyword>
	<keyword>larynx</keyword>
	<keyword>nasopharynx</keyword>
	<keyword>oral cavity</keyword>
	<keyword>prospective study</keyword>
	<keyword>predictive model HNSCC</keyword>
	<keyword>genomic analysis</keyword>
	<keyword>outcome prediction</keyword>
</DOC>